New Delhi, Aug 13 (PTI) Glenmark Pharmaceuticals on Friday said its consolidated profit after tax (PAT) increased by 21 per cent to Rs 306 crore for the first quarter ended June 30.

The Mumbai-based drug major had reported a PAT of Rs 254 crore in the April-June quarter of the 2020-21 fiscal.

Also Read | India's Foreign Exchange Reserves Rise by Over USD 880 Million During the Week Ended August 6, Says RBI Report.

The company's consolidated revenue rose to Rs 2,965 crore from Rs 2,345 crore in the Q1 of last fiscal.

"It was a landmark quarter for the company with positive momentum in all our key markets. Our commitment towards the fight against COVID-19 was reflected in FabiFlu becoming the number one brand in the India pharma market in April.

Also Read | Aryan Tripathi, Founder of Adymize - One of the Best Advertising Agencies in India.

"We launched our first nebuliser, Arformoterol Inhalation solution from Monroe, US," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said in a statement.

The company has a strategic roadmap to grow consistently and profitably over the year, he added.

"We have a clear plan in place to reduce debt by enhancing free cash, prioritising over R&D investments and capital expenditure going forward," Saldanha noted.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)